Modulation of T cell responses to recall antigens presented by Langerhans cells in HIV-discordant identical twins by anti-interleukin (IL)-10 antibodies and IL-12.

af Blauvelt, A, Chougnet, C, Shearer, G M, Katz, S I
Udgivet 1996

Concerns and perceptions of patients with psoriatic disease during the COVID‐19 pandemic: results from a two‐wave survey by the National Psoriasis Foundation

af Gondo, G.C., Bell, S.J., Slayden, J., Ullmann, G., Blauvelt, A.
Udgivet i J Eur Acad Dermatol Venereol (2021)

Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–asses...

af Warren, R.B., Blauvelt, A., Poulin, Y., Beeck, S., Kelly, M., Wu, T., Geng, Z., Paul, C.
Udgivet i Br J Dermatol (2020)

Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways.

af Blauvelt, A, Asada, H, Saville, M W, Klaus-Kovtun, V, Altman, D J, Yarchoan, R, Katz, S I
Udgivet 1997

Demographics, clinical disease characteristics, and quality of life in a large cohort of psoriasis patients with and without psoriatic arthritis

af Truong, B, Rich-Garg, N, Ehst, BD, Deodhar, AA, Ku, JH, Vakil-Gilani, K, Danve, A, Blauvelt, A
Udgivet i Clin Cosmet Investig Dermatol (2015)

Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate‐to‐severe psoriasis: a pooled analysis of two randomized controlled trials

af Blauvelt, A., Sofen, H., Papp, K., Gooderham, M., Tyring, S., Zhao, Y., Lowry, S., Mendelsohn, A., Parno, J., Reich, K.
Udgivet i J Eur Acad Dermatol Venereol (2019)

Certolizumab pegol for the treatment of patients with moderate‐to‐severe chronic plaque psoriasis: pooled analysis of week 16 data from three randomized controlled trials

af Blauvelt, A., Reich, K., Lebwohl, M., Burge, D., Arendt, C., Peterson, L., Drew, J., Rolleri, R., Gottlieb, A.B.
Udgivet i J Eur Acad Dermatol Venereol (2018)

Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III stu...

af Kimball, A.B., Papp, K.A., Reich, K., Gooderham, M., Li, Q., Cichanowitz, N., La Rosa, C., Blauvelt, A.
Udgivet i Br J Dermatol (2019)

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab

af Kimball, A.B., Kerbusch, T., van Aarle, F., Kulkarni, P., Li, Q., Blauvelt, A., Papp, K.A., Reich, K., Montgomery, D.
Udgivet i Br J Dermatol (2019)

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐wee...

af Blauvelt, A., Reich, K., Mehlis, S., Vanaclocha, F., Sofen, H., Abramovits, W., Zhao, Y., Gilloteau, I., Davenport, E., Williams, N., Guana, A., Tyring, S.
Udgivet i J Eur Acad Dermatol Venereol (2017)

Patient‐reported symptoms and signs of moderate‐to‐severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial

af Papp, K.A., Blauvelt, A., Kimball, A.B., Han, C., Randazzo, B., Wasfi, Y., Shen, Y.‐K., Li, S., Griffiths, C.E.M.
Udgivet i J Eur Acad Dermatol Venereol (2018)

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52‐week results from a doubl...

af Bagel, J., Blauvelt, A., Nia, J., Hashim, P., Patekar, M., de Vera, A., Ahmad, K., Paguet, B., Xia, S., Muscianisi, E., Lebwohl, M.
Udgivet i J Eur Acad Dermatol Venereol (2020)

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2)

af Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.
Udgivet i Br J Dermatol (2020)

Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-mar...

af Deodhar, A., Mease, P. J., McInnes, I. B., Baraliakos, X., Reich, K., Blauvelt, A., Leonardi, C., Porter, B., Das Gupta, A., Widmer, A., Pricop, L., Fox, T.
Udgivet i Arthritis Res Ther (2019)

Long‐term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo‐controlled studies

af Blauvelt, A., Paul, C., van de Kerkhof, P., Warren, R.B., Gottlieb, A.B., Langley, R.G., Brock, F., Arendt, C., Boehnlein, M., Lebwohl, M., Reich, K.
Udgivet i Br J Dermatol (2020)

Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials

af Blauvelt, A., Rosmarin, D., Bieber, T., Simpson, E.L., Bagel, J., Worm, M., Deleuran, M., Katoh, N., Kawashima, M., Shumel, B., Chen, Z., Rossi, A.B., Hultsch, T., Ardeleanu, M.
Udgivet i Br J Dermatol (2019)

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis

af Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.
Udgivet i J Eur Acad Dermatol Venereol (2017)

Long‐term efficacy and safety of tildrakizumab for moderate‐to‐severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 1...

af Reich, K., Warren, R.B., Iversen, L., Puig, L., Pau‐Charles, I., Igarashi, A., Ohtsuki, M., Falqués, M., Harmut, M., Rozzo, S., Lebwohl, M.G., Cantrell, W., Blauvelt, A., Thaçi, D.
Udgivet i Br J Dermatol (2019)

Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)

af Wollenberg, A., Beck, L.A., Blauvelt, A., Simpson, E.L., Chen, Z., Chen, Q., Shumel, B., Khokhar, F.A., Hultsch, T., Rizova, E., Rossi, A.B., Graham, N.M.H., Pirozzi, G., Lu, Y., Ardeleanu, M.
Udgivet i Br J Dermatol (2019)

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, doubl...

af Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.
Udgivet i Br J Dermatol (2020)